No Detail Found!

Association of Body Mass Index with Clopidogrel Resistance.

Author(s)
Usman Nawaz Department of Pharmacology and Therapeutics, Army Medical College, National University of Sciences and Technology, Islamabad, Pakistan
Mudassar Noor Department of Pharmacology and Therapeutics, Army Medical College, National University of Sciences and Technology, Islamabad, Pakistan
Chaudhry Altaf Department of Haematology, Armed Forces Institute of Pathology, Department of Pharmacology and Therapeutics, Army Medical College, National University of Medical Science, Rawalpindi, Pakistan
Akbar Waheed Department of Pharmacology and Therapeutics, Army Medical College, National University of Sciences and Technology, Islamabad, Pakistan
Saleem Ahmad Khan Department of Haematology, Armed Forces Institute of Pathology, Department of Pharmacology and Therapeutics, Army Medical College, National University of Medical Science, Rawalpindi, Pakistan
Abstract
Background: Clopidogrel is an essential component of dual antiplatelet treatment for ischemic heart disease. We planned to explore the association of body mass index with clopidogrel resistance in ischemic heart disease patients. Methods: Three hundred and ninety patients of ischemic heart disease who were taking clopidogrel 75mg/day, were included in the study. Patients were categorized according to their body mass index (BMI) into underweight (BMI25 Kg/m2). Their blood samples were taken and platelet aggregation studies were performed using Chronolog light transmission aggregometer to confirm clopidogrel resistant status. Results: None of the underweight, 19.50% of the normal weight, 24.20% of the overweight and 33.60% of the obese patients were found to be clopidogrel resistant. Clopidogrel resistance was significantly higher in obese patients as compared to normal weight patients, p=0.019. No significant difference in clopidogrel response was found between normal weight and overweight patients, as well as overweight and obese patients. Mean BMI of clopidogrel resistant patients was significantly higher than mean BMI of clopidogrel responders (26.46±3.82 vs 24.15±3.39 Kg/m2), p<0.001. Correlation between BMI and platelet aggregation was significant (p<0.001, r=0.20). Conclusion: BMI is inversely related to the platelet inhibition by clopidogrel. Higher BMI is related to clopidogrel resistance in ischemic heart disease patients.
Publication Details
Page(s) 50-53
DOI DOI not available
Published Journal: Pakistan Journal of Physiology, Volume: 14, Issue: 3, Year: 2018

Request the full text from PASTIC

References
BashirS,PoornimaR,,2016,Pharmacogenetic variations related to clopidogrel resistance and its clinical implications: An issue which remains largely unaddressed,Asian J Pharm Clin Res,9,194-6
GallottaA,MarengoniA,PasinaL,CortesiL,NobiliA,,2017,Prevalence of older in-patients at risk of clopidogrel resistance according to the STIB score. Results from REPOSI registry,Eur J Intern Med,41,e17-8
WuZK,WangJJ,WangT,ZhuSS,ChenXL,LiuC,,2015,Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity,J Geriatr Cardiol,12,378-82
WangZJ,ZhouYJ,LiuYY,YuM,ShiDM,ZhaoYX,,2009,Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent,Thromb Res,124,46-51
CuiG,ZhangS,ZouJ,ChenY,ChenH.,,2017,P2Y12 receptor gene polymorphism and the risk of resistance to clopidogrel: A metaanalysis and review of the literature,Adv Clin Exp Med,26,343-9
Bonello-PalotN,ArmeroS,PaganelliF,ManciniJ,De LabriolleA,BonelloC,,2009,Relation of body mass index to high ontreatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention,Am J Cardiol,104,1511-5
Al-AzzamSI,AlzoubiKH,KhabourOF,NusairMB,Al-HadidiH,AwidiA,,2013,Factors that contribute to clopidogrel resistance in cardiovascular disease patients: environmental and genetic approach,Int J Clin Pharmacol Ther,51,179-86
ShetkarSS,RamakrishnanS,SethS,ChandnaP,VermaSK,BhargavaB,,2014,CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease,Indian Heart J,66,16-24
ShaliaKK,ShahVK,PawarP,DivekarSS,PayannavarS.,,2013,Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: Effects on clopidogrel response,Indian Heart J,65,158-67
HumayunA,ShahAS,AlamS,HusseinH,,2009,Relationship of body mass index and dyslipidemia in different age groups of male and female population of Peshawar,J Ayub Med Coll Abbottabad,21,141-4
AngiolilloDJ,Fernandez-OrtizA,BernardoE,RamírezC,SabatéM,Jimenez-QuevedoP,,2005,Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment,Diabetes,54,2430-5
GurbelPA,TantryUS,,2007,,Clopidogrel resistance? Thromb Res,120,311-21
,2006,Profile and prevalence of clopidogrel resistance in patients of acute coronary syndrome,Indian Heart J,59,152-6
BlidenKP,DiChiaraJ,TantryUS,BassiAK,ChagantiSK,GurbelPA,,2007,Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention,J Am Coll Cardiol,49,657-66
PengFei,,2017,Analysis of clopidogrel resistance and its influencing factors in patients with ischemic stroke and transient ischemic attack,Chinese J Clin Neurosci,3,10-
FeherG,KoltaiK,AlkonyiB,PappE,KeszthelyiZ,KesmarkyG,,2007,Clopidogrel resistance: role of body mass and concomitant medications,Int J Cardiol,120,188-92
WangL,WangX,ChenF,,2010,Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents,Drugs in R & D,10,219-24
DentaliF,SquizzatoA,AgenoW.,,2009,The metabolic syndrome as a risk factor for venous and arterial thrombosis,Semin Thromb Hemost,35,451-7
,2005,Hypercoagulability in the metabolic syndrome,Curr Opin Pharmacol,5,155-9
AnfossiG,RussoI,TrovatiM.,,2009,Platelet dysfunction in central obesity,Nutr Metab Cardiovasc Dis,19,440-9
KonstantinidesS,SchäferK,KoschnickS,LoskutoffDJ,,2001,Leptindependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity,J Clin Invest,108,1533-40
DavìG,GuagnanoMT,CiabattoniG,BasiliS,FalcoA,MarinopiccoliM,,2002,Platelet activation in obese women: role of inflammation and oxidant stress,JAMA,288,2008-14
0

Citations

0

Downloads

48

Views